호르몬 피임약 시장(2026-2030년)

The global hormonal contraceptives market is forecasted to grow by USD 4875.3 mn during 2025-2030, accelerating at a CAGR of 4.3% during the forecast period. The report on the global hormonal contraceptives market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising awareness of family planning, technological advancements in delivery, expansion of e-commerce channels.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global hormonal contraceptives market is segmented as below:

By Method

• Oral contraceptives
• Implanted contraceptives
• Injected contraceptives
• Intrauterine
• Others

By Age Group

• 25 to 34 years
• 15 to 24 years
• 35 to 44 years
• Above 44 years

By End-User

• Homecare settings
• Hospitals
• Clinics

Geography

• North America
  • US
  • Canada
  • Mexico
• Asia
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the rising preference for reversible options as one of the prime reasons driving the global hormonal contraceptives market growth during the next few years. Also, shift toward progestin only regimens and technological innovation in low dose formulations will lead to sizable demand in the market.

The report on the global hormonal contraceptives market covers the following areas:

• Global hormonal contraceptives market sizing
• Global hormonal contraceptives market forecast
• Global hormonal contraceptives market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global hormonal contraceptives market vendors that include AbbVie Inc., Agile Therapeutics Inc., Amneal Pharmaceuticals Inc., ASKA Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Bayer AG, Cipla Inc., Exeltis Pharmaceuticals Holding, Fuji Pharma Co. Ltd., Gedeon Richter Plc, Glenmark Pharmaceuticals Ltd., HLL Lifecare Ltd., Lupin Ltd., Mankind Pharma Ltd., Mayne Pharma Group Ltd., Organon and Co., Perrigo Co. Plc, Pfizer Inc., Piramal Pharma Solutions, Shanghai Dahua Pharmaceutical, Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd., Viatris Inc.. Also, the global hormonal contraceptives market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Method
  • Executive Summary - Chart on Market Segmentation by Age Group
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Hormonal Contraceptives Market 2020 - 2024
  • Historic Market Size - Data Table on Global Hormonal Contraceptives Market 2020 - 2024 ($ million)
• 5.2 Method segment analysis 2020 - 2024
  • Historic Market Size - Method Segment 2020 - 2024 ($ million)
• 5.3 Age Group segment analysis 2020 - 2024
  • Historic Market Size - Age Group Segment 2020 - 2024 ($ million)
• 5.4 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Hormonal Contraceptives Market
• 6.2 Impact of geopolitical conflicts on Global Hormonal Contraceptives Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Method

• 8.1 Market segments
• 8.2 Comparison by Method
• 8.3 Oral contraceptives - Market size and forecast 2025-2030
• 8.4 Implanted contraceptives - Market size and forecast 2025-2030
• 8.5 Injected contraceptives - Market size and forecast 2025-2030
• 8.6 Intrauterine - Market size and forecast 2025-2030
• 8.7 Others - Market size and forecast 2025-2030
• 8.8 Market opportunity by Method
  • Market opportunity by Method ($ million)

9 Market Segmentation by Age Group

• 9.1 Market segments
• 9.2 Comparison by Age Group
• 9.3 25 to 34 years - Market size and forecast 2025-2030
• 9.4 15 to 24 years - Market size and forecast 2025-2030
• 9.5 35 to 44 years - Market size and forecast 2025-2030
• 9.6 Above 44 years - Market size and forecast 2025-2030
• 9.7 Market opportunity by Age Group
  • Market opportunity by Age Group ($ million)

10 Market Segmentation by End-user

• 10.1 Market segments
• 10.2 Comparison by End-user
• 10.3 Homecare settings - Market size and forecast 2025-2030
• 10.4 Hospitals - Market size and forecast 2025-2030
• 10.5 Clinics - Market size and forecast 2025-2030
• 10.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Asia - Market size and forecast 2025-2030
  • 12.4.1 China - Market size and forecast 2025-2030
  • 12.4.2 Japan - Market size and forecast 2025-2030
  • 12.4.3 India - Market size and forecast 2025-2030
  • 12.4.4 Thailand - Market size and forecast 2025-2030
  • 12.4.5 South Korea - Market size and forecast 2025-2030
  • 12.4.6 Indonesia - Market size and forecast 2025-2030
• 12.5 Europe - Market size and forecast 2025-2030
  • 12.5.1 Germany - Market size and forecast 2025-2030
  • 12.5.2 UK - Market size and forecast 2025-2030
  • 12.5.3 France - Market size and forecast 2025-2030
  • 12.5.4 Italy - Market size and forecast 2025-2030
  • 12.5.5 Spain - Market size and forecast 2025-2030
  • 12.5.6 The Netherlands - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Argentina - Market size and forecast 2025-2030
  • 12.6.5 South Africa - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 Turkey - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Rising awareness of family planning
  • Technological advancements in delivery
  • Expansion of E-commerce channels
• 13.2 Market challenges
  • Adverse health risks and side effects
  • Cultural stigma and educational barriers
  • Complex regulatory hurdles and approvals
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Rising preference for reversible options
  • Shift toward progestin only regimens
  • Technological innovation in low dose formulations

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
• 15.5 Amneal Pharmaceuticals Inc.
  • Amneal Pharmaceuticals Inc. - Overview
  • Amneal Pharmaceuticals Inc. - Business segments
  • Amneal Pharmaceuticals Inc. - Key offerings
  • Amneal Pharmaceuticals Inc. - Segment focus
  • SWOT
• 15.6 ASKA Pharmaceutical Co. Ltd.
  • ASKA Pharmaceutical Co. Ltd. - Overview
  • ASKA Pharmaceutical Co. Ltd. - Product / Service
  • ASKA Pharmaceutical Co. Ltd. - Key offerings
  • SWOT
• 15.7 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Business segments
  • Aurobindo Pharma Ltd. - Key news
  • Aurobindo Pharma Ltd. - Key offerings
  • Aurobindo Pharma Ltd. - Segment focus
  • SWOT
• 15.8 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.9 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.10 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.11 Mankind Pharma Ltd.
  • Mankind Pharma Ltd. - Overview
  • Mankind Pharma Ltd. - Business segments
  • Mankind Pharma Ltd. - Key news
  • Mankind Pharma Ltd. - Key offerings
  • Mankind Pharma Ltd. - Segment focus
  • SWOT
• 15.12 Organon and Co.
  • Organon and Co. - Overview
  • Organon and Co. - Product / Service
  • Organon and Co. - Key offerings
  • SWOT
• 15.13 Perrigo Co. Plc
  • Perrigo Co. Plc - Overview
  • Perrigo Co. Plc - Business segments
  • Perrigo Co. Plc - Key offerings
  • Perrigo Co. Plc - Segment focus
  • SWOT
• 15.14 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.15 Piramal Pharma Solutions
  • Piramal Pharma Solutions - Overview
  • Piramal Pharma Solutions - Business segments
  • Piramal Pharma Solutions - Key offerings
  • Piramal Pharma Solutions - Segment focus
  • SWOT
• 15.16 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Business segments
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • Sun Pharmaceutical Industries - Segment focus
  • SWOT
• 15.17 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.18 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations